{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:29:03Z","timestamp":1778646543592,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2020R1A2C1006996"],"award-info":[{"award-number":["2020R1A2C1006996"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CAGE, a cancer\/testis antigen, was originally isolated from the sera of patients with gastric cancers. Previously, we have shown the role of CAGE in resistance to chemotherapy and target therapy. The aim of this study was to investigate the role of CAGE in osimertinib resistance and determine the prognostic value of CAGE in patients with pulmonary adenocarcinomas. The clinicopathological correlation with CAGE and autophagy flux in patients was examined using immunohistochemistry and in situ hybridization. The possible role of autophagy in osimertinib resistance was analyzed using immune blot, immune fluorescence staining and immunohistochemistry. This study found that immunohistochemical staining (IHC) showed CAGE expression in more than 50% of patients with pulmonary adenocarcinomas (pADCs). CAGE expression was increased in pADCs after the acquisition of EGFR-TKIs resistance. High expression of CAGE was correlated with shorter overall survival and progression free survival in patients with pADCs. Thus, CAGE mediates osimertinib resistance and predicts poor prognosis in patients with pADCs. Osimertinib-resistant non-small cell lung cancer cells (PC-9\/OSI) were established and mechanistic studies of CAGE-mediated osimertinib resistance were performed. PC-9\/OSI cells showed increased autophagic flux and CAGE expression compared with parental sensitive PC-9 cells. PC-9\/OSI cells showed higher tumorigenic, metastatic, and angiogenic potential compared with parental PC-9 cells. CAGE CRISPR-Cas9 cell lines showed decreased autophagic flux, invasion, migration potential, and tumorigenic potential compared with PC-9\/OSI cells in vitro and in vivo. CAGE plays a crucial role in the cancer progression by modulating autophagy and can predict the poor prognosis of patients with pulmonary adenocarcinomas. Our findings propose CAGE as a potential therapeutic target for developing anticancer drugs that can overcome osimertinib resistance.<\/jats:p>","DOI":"10.1038\/s41598-023-43124-8","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T13:02:16Z","timestamp":1695301336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cancer\/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Minjeong","family":"Yeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hankyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongseon","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeong Seon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Suk","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyerim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeonghee","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyein","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doyong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaemoon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dooil","family":"Jeoung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"43124_CR1","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","volume":"8","author":"NM Andrews Wright","year":"2019","unstructured":"Andrews Wright, N. M. & Goss, G. D. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl. Lung Cancer Res. 8, S247\u2013S264. https:\/\/doi.org\/10.21037\/tlcr.2019.06.01 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"43124_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.neo.2021.06.006)","volume":"23","author":"L Deng","year":"2021","unstructured":"Deng, L., Vallega, K. A., Zhang, S., Shi, P. & Sun, S. Y. MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription. Neoplasia 23, 766\u2013774. https:\/\/doi.org\/10.1016\/j.neo.2021.06.006) (2021).","journal-title":"Neoplasia"},{"key":"43124_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/carcin\/bgab030","volume":"42","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy. Carcinogenesis 42, 880\u2013890. https:\/\/doi.org\/10.1093\/carcin\/bgab030 (2021).","journal-title":"Carcinogenesis"},{"key":"43124_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","volume":"39","author":"K Tanaka","year":"2021","unstructured":"Tanaka, K. et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell 39, 1245\u20131261. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.006 (2021).","journal-title":"Cancer Cell"},{"key":"43124_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12935-021-02056-x","volume":"21","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness. Cancer Cell Int. 21, 337. https:\/\/doi.org\/10.1186\/s12935-021-02056-x (2021).","journal-title":"Cancer Cell Int."},{"key":"43124_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers13143441","volume":"13","author":"M Mancini","year":"2021","unstructured":"Mancini, M. et al. Generation and characterization of a new preclinical mouse model of EGFR-driven lung cancer with MET-induced osimertinib resistance. Cancers (Basel) 13, 14. https:\/\/doi.org\/10.3390\/cancers13143441 (2021).","journal-title":"Cancers (Basel)"},{"key":"43124_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-021-00181-4","volume":"5","author":"NJ Gurule","year":"2021","unstructured":"Gurule, N. J. et al. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ Precis. Oncol. 5, 41. https:\/\/doi.org\/10.1038\/s41698-021-00181-4 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"43124_CR8","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1158\/0008-5472.CAN-20-3790","volume":"81","author":"H Choi","year":"2021","unstructured":"Choi, H. et al. Targeting DDX3X triggers antitumor immunity via a dsRNA-mediated tumor-intrinsic type I interferon response. Cancer Res. 81, 3607\u20133620. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3790 (2021).","journal-title":"Cancer Res."},{"key":"43124_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12935-021-01914-y","volume":"21","author":"Y Meng","year":"2021","unstructured":"Meng, Y. et al. Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma. Cancer Cell Int. 21, 216. https:\/\/doi.org\/10.1186\/s12935-021-01914-y (2021).","journal-title":"Cancer Cell Int."},{"key":"43124_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1006\/bbrc.2002.6701","volume":"292","author":"B Cho","year":"2002","unstructured":"Cho, B. et al. Identification and characterization of a novel cancer\/testis antigen gene CAGE. Biochem. Biophys. Res. Commun. 292, 715\u2013726. https:\/\/doi.org\/10.1006\/bbrc.2002.6701 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"43124_CR11","doi-asserted-by":"publisher","first-page":"1824642","DOI":"10.1080\/2162402X.2020.1824642","volume":"9","author":"AM Hurtado Lopez","year":"2020","unstructured":"Hurtado Lopez, A. M. et al. Cancer testis antigens in myelodysplastic syndromes revisited: A targeted RNA-seq approach. Oncoimmunology 9, 1824642. https:\/\/doi.org\/10.1080\/2162402X.2020.1824642 (2020).","journal-title":"Oncoimmunology"},{"key":"43124_CR12","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1158\/1078-0432.CCR-04-1702","volume":"11","author":"T Iwata","year":"2005","unstructured":"Iwata, T. et al. Frequent immune responses to a cancer\/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin. Cancer Res. 11, 3949\u20133957. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1702 (2005).","journal-title":"Clin. Cancer Res."},{"key":"43124_CR13","doi-asserted-by":"publisher","first-page":"13632","DOI":"10.18632\/oncotarget.14621","volume":"8","author":"Y Kim","year":"2017","unstructured":"Kim, Y. et al. The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3beta and decreasing the expression of cyclinD1. Oncotarget 8, 13632\u201313651. https:\/\/doi.org\/10.18632\/oncotarget.14621 (2017).","journal-title":"Oncotarget"},{"key":"43124_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/JCMA.0000000000000438","volume":"84","author":"ND Verusingam","year":"2021","unstructured":"Verusingam, N. D. et al. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R\/T790M mutant non-small cell lung carcinoma cell line. J. Chin. Med. Assoc. 84, 248\u2013254 (2021).","journal-title":"J. Chin. Med. Assoc."},{"key":"43124_CR15","doi-asserted-by":"publisher","first-page":"666387","DOI":"10.3389\/fcell.2021.666387","volume":"9","author":"M Yeon","year":"2021","unstructured":"Yeon, M. et al. The CAGE-MiR-181b-5p-S1PR1 axis regulates anticancer drug resistance and autophagy in gastric cancer cells. Front. Cell Dev. Biol. 9, 666387. https:\/\/doi.org\/10.3389\/fcell.2021.666387 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"43124_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","volume":"28","author":"J Koh","year":"2015","unstructured":"Koh, J. et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: Comparison with histology and driver oncogenic alteration status. Mod. Pathol. 28, 1154\u20131166. https:\/\/doi.org\/10.1038\/modpathol.2015.63 (2015).","journal-title":"Mod. Pathol."},{"key":"43124_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11427-018-9357-y","volume":"62","author":"H Xia","year":"2019","unstructured":"Xia, H. et al. Protective effects of autophagy against blue light-induced retinal degeneration in aged mice. Sci. China Life Sci. 62, 244\u2013256. https:\/\/doi.org\/10.1007\/s11427-018-9357-y (2019).","journal-title":"Sci. China Life Sci."},{"key":"43124_CR18","doi-asserted-by":"crossref","unstructured":"Singh, A. B. EGFR-signaling and autophagy: How they fit in the cancer landscape.\u00a0J. Adenocarcinoma\u00a01\u00a0(2016).","DOI":"10.21767\/2572-309X.100009"},{"key":"43124_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers13153917","volume":"13","author":"D Bellanger","year":"2021","unstructured":"Bellanger, D. et al. Adipocytes promote breast cancer cell survival and migration through autophagy activation. Cancers (Basel) 13, 15. https:\/\/doi.org\/10.3390\/cancers13153917 (2021).","journal-title":"Cancers (Basel)"},{"key":"43124_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091374","author":"Y Kwon","year":"2019","unstructured":"Kwon, Y., Kim, M., Jung, H. S., Kim, Y. & Jeoung, D. Targeting autophagy for overcoming resistance to anti-EGFR treatments. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11091374 (2019).","journal-title":"Cancers (Basel)"},{"key":"43124_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3389\/fonc.2018.00599","volume":"8","author":"M Yeon","year":"2018","unstructured":"Yeon, M. et al. CAGE binds to Beclin1, regulates autophagic flux and CAGE-derived peptide confers sensitivity to anti-cancer drugs in non-small cell lung cancer cells. Front. Oncol. 8, 599. https:\/\/doi.org\/10.3389\/fonc.2018.00599 (2018).","journal-title":"Front. Oncol."},{"key":"43124_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.14348\/molcells.2017.0001","volume":"40","author":"Y Kim","year":"2017","unstructured":"Kim, Y. et al. DDX53 regulates cancer stem cell-like properties by binding to SOX-2. Mol. Cells 40, 322\u2013330. https:\/\/doi.org\/10.14348\/molcells.2017.0001 (2017).","journal-title":"Mol. Cells"},{"key":"43124_CR23","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1111\/cas.15036","volume":"112","author":"R Yiming","year":"2021","unstructured":"Yiming, R. et al. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Cancer Sci. 112, 3810\u20133821. https:\/\/doi.org\/10.1111\/cas.15036 (2021).","journal-title":"Cancer Sci."},{"key":"43124_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12885-016-2416-9","volume":"16","author":"K Harada","year":"2016","unstructured":"Harada, K. et al. Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors. BMC Cancer 16, 548. https:\/\/doi.org\/10.1186\/s12885-016-2416-9 (2016).","journal-title":"BMC Cancer"},{"key":"43124_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrd.2017.22","volume":"16","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R. & Kroemer, G. Pharmacological modulation of autophagy: Therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 16, 487\u2013511. https:\/\/doi.org\/10.1038\/nrd.2017.22 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"43124_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.canlet.2018.07.028","volume":"435","author":"M Dyczynski","year":"2018","unstructured":"Dyczynski, M. et al. Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. Cancer Lett. 435, 32\u201343. https:\/\/doi.org\/10.1016\/j.canlet.2018.07.028 (2018).","journal-title":"Cancer Lett."},{"key":"43124_CR27","doi-asserted-by":"publisher","first-page":"17848","DOI":"10.1073\/pnas.1908228116","volume":"116","author":"A Totaro","year":"2019","unstructured":"Totaro, A. et al. Cell phenotypic plasticity requires autophagic flux driven by YAP\/TAZ mechanotransduction. Proc. Natl. Acad. Sci. U. S. A. 116, 17848\u201317857. https:\/\/doi.org\/10.1073\/pnas.1908228116 (2019).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"43124_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040804","author":"D Konig","year":"2021","unstructured":"Konig, D., SavicPrince, S. & Rothschild, S. I. Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13040804 (2021).","journal-title":"Cancers (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43124-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:26:57Z","timestamp":1700605617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43124"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43124-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1885087\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15748"}}